CONSORT 2010 flow diagram.

<p>CHC patients who were enrolled and followed up. 93 patients were screened for participation in the study. 13 patients were excluded. 80 patients were randomly assigned to receive a placebo or vitamin D supplements and followed up after six weeks of supplements. BMJ 2010;340:c869. doi:<a href="http://dx.doi.org/10.1136/bmj.c869" target="_blank">10.1136/bmj.c869</a>.</p

Comparing mean serum levels of each parameter between pre-and post-supplements in placebo and vitamin D groups.

<p>Comparing mean serum levels of each parameter between pre-and post-supplements in placebo and vitamin D groups.</p

Baseline characteristics of CHC patients in the placebo and vitamin D groups.

<p>Baseline characteristics of CHC patients in the placebo and vitamin D groups.</p

Allele and genotype frequencies of six VDR SNPs including <i>CdX-2</i>, <i>GATA</i>, <i>Fok</i>I, <i>Bsm</i>l, <i>Apa</i>I and <i>Taq</i>I in patients with HBeAg positive (N 62) and negative (N 254).

(DOCX)</p

Comparing changes in serum levels (or delta) of each parameter in placebo and vitamin D groups during 6-week period of supplement.

<p>Comparing changes in serum levels (or delta) of each parameter in placebo and vitamin D groups during 6-week period of supplement.</p

Mean changes of vitamin D levels.

<p>(A), IP-10 (B) and DPP IV (C) levels after 6-week supplements in placebo and vitamin D groups were demonstrated. The x-axis of each graph represents mean changes of the levels (delta). The blue and orange boxes represent placebo group and vitamin D group, respectively.</p

Scatter plot of post treatment VD levels (x-axis) and post treatment IP-10 level (y-axis) including fit line and regression equation were demonstrated.

<p>Scatter plot of post treatment VD levels (x-axis) and post treatment IP-10 level (y-axis) including fit line and regression equation were demonstrated.</p

Baseline characteristics of patients with HBV inactive carrier (IC) and chronic hepatitis (CH) phases.

Baseline characteristics of patients with HBV inactive carrier (IC) and chronic hepatitis (CH) phases.</p

Haplotype frequencies of six VDR SNPs including <i>CdX-2</i>, <i>GATA</i>, <i>Fok</i>I, <i>Bsm</i>l, <i>Apa</i>I and <i>Taq</i>I in patients with HBeAg positive (N 62) and negative (N 254).

(DOCX)</p

Univariate and multivariate regression analysis of factors associated with HBV inactive carrier (IC) phase.

Univariate and multivariate regression analysis of factors associated with HBV inactive carrier (IC) phase.</p